Cargando…

SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects

OBJECTIVES: The worldwide spread of coronavirus disease 2019 (COVID-19) highlights the need for assessment of long-term humoral immunity in convalescent subjects. Our objectives were to evaluate long-term IgG antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and B-cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Achiron, Anat, Gurevich, Michael, Falb, Rina, Dreyer-Alster, Sapir, Sonis, Polina, Mandel, Mathilda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106530/ https://www.ncbi.nlm.nih.gov/pubmed/33975009 http://dx.doi.org/10.1016/j.cmi.2021.05.008

Ejemplares similares

SARS‐CoV‐2 memory B and T cell profiles in mild COVID‐19 convalescent patients
por: Gurevich, Michael, et al.
Publicado: (2022)

COVID‐19 Alpha Variant (B.1.1.7): Humoral, memory B and T cells in COVID‐19 pediatric convalescents
por: Gurevich, Michael, et al.
Publicado: (2022)

Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod
por: Achiron, Anat, et al.
Publicado: (2022)

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
por: Achiron, Anat, et al.
Publicado: (2021)

Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
por: Achiron, Anat, et al.
Publicado: (2021)

Humoral SARS-COV-2 IgG decay within 6 months in COVID-19 healthy vaccinees: The need for a booster vaccine dose?
por: Achiron, Anat, et al.
Publicado: (2021)

In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab
por: Achiron, Anat, et al.
Publicado: (2023)

Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study
por: Achiron, Anat, et al.
Publicado: (2021)

COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose
por: Dreyer-Alster, Sapir, et al.
Publicado: (2022)

Optical Coherence Tomography Is Associated With Cognitive Impairment in Multiple Sclerosis
por: Dreyer-Alster, Sapir, et al.
Publicado: (2022)

Intravenous immunoglobulin treatment during pregnancy and the post-partum period in women with multiple sclerosis: A prospective analysis
por: Menascu, Shay, et al.
Publicado: (2023)

Cytokine prediction of mortality in COVID19 patients
por: Mandel, Mathilda, et al.
Publicado: (2020)

COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021
por: Achiron, Anat, et al.
Publicado: (2021)

Faster progression to multiple sclerosis disability is linked to neuronal pathways associated with neurodegeneration: An ethnicity study
por: Harari, Gil, et al.
Publicado: (2023)

Unique Gene Expression Patterns in Human T-cell Lines Generated from Multiple Sclerosis Patients by Stimulation with a Synthetic MOG Peptide
por: Mandel, Mathilda, et al.
Publicado: (2005)

RAM-589.555 favors neuroprotective and anti-inflammatory profile of CNS-resident glial cells in acute relapse EAE affected mice
por: Zilkha-Falb, Rina, et al.
Publicado: (2020)

No evidence for an association between alcohol consumption and Multiple Sclerosis risk: a UK Biobank study
por: Dreyer-Alster, Sapir, et al.
Publicado: (2022)

Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis
por: Gurevich, Michael, et al.
Publicado: (2015)

Clinical and transcriptional recovery profiles in pediatric and adult multiple sclerosis patients
por: Menascu, Shay, et al.
Publicado: (2020)

Longitudinal relationships between disability and gait characteristics in people with MS
por: Dreyer-Alster, Sapir, et al.
Publicado: (2022)

Motoric cognitive risk syndrome in people with multiple sclerosis: prevalence and correlations with disease-related factors
por: Dreyer-Alster, Sapir, et al.
Publicado: (2022)

Targeted cognitive game training enhances cognitive performance in multiple sclerosis patients treated with interferon beta 1-a
por: Menascu, Shay, et al.
Publicado: (2021)

Comparing SARS-CoV-2 neutralizing antibody levels in convalescent unvaccinated, convalescent vaccinated, and naive vaccinated subjects
por: Dulipsingh, Latha, et al.
Publicado: (2023)

Molecular Profiling of Glatiramer Acetate Early Treatment Effects in Multiple Sclerosis
por: Achiron, Anat, et al.
Publicado: (2009)

Optimizing multiple sclerosis diagnosis: gene expression and genomic association
por: Gurevich, Michael, et al.
Publicado: (2015)

Evaluation and correlation between SARS-CoV-2 neutralizing and binding antibodies in convalescent and vaccinated subjects
por: Manenti, Alessandro, et al.
Publicado: (2022)

Maintenance of neutralizing antibodies over ten months in convalescent SARS‐CoV‐2 afflicted patients
por: Sonnleitner, Sissy Therese, et al.
Publicado: (2021)

Antibody response against SARS-CoV-2 in convalescent plasma donors: Can we predict subjects’ eligibility?
por: Prudente, Tiago Paiva, et al.
Publicado: (2022)

Prediction of acute multiple sclerosis relapses by transcription levels of peripheral blood cells
por: Gurevich, Michael, et al.
Publicado: (2009)

Suppressed RNA-Polymerase 1 Pathway Is Associated with Benign Multiple Sclerosis
por: Achiron, Anat, et al.
Publicado: (2012)

Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
por: Robbiani, Davide F., et al.
Publicado: (2020)

Dynamics of antibodies to SARS‐CoV‐2 in convalescent plasma donors
por: Steenhuis, Maurice, et al.
Publicado: (2021)

Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma
por: Natarajan, Harini, et al.
Publicado: (2021)

The intercorrelations between blood levels of ferritin, sCD163, and IL-18 in COVID-19 patients and their association to prognosis
por: Volfovitch, Yuval, et al.
Publicado: (2022)

Understanding Autoimmune Mechanisms in Multiple Sclerosis Using Gene Expression Microarrays: Treatment Effect and Cytokine-related Pathways
por: Achiron, A., et al.
Publicado: (2004)

Prefrontal hemodynamics during forward and backward walking, with and without a cognitive task, in people with multiple sclerosis
por: KUPCHENKO, Yana, et al.
Publicado: (2023)

Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals
por: Robbiani, Davide F., et al.
Publicado: (2020)

Sensitivity of SARS-CoV-2 antibody tests with late convalescent sera
por: Kannenberg, Judith, et al.
Publicado: (2021)

Differential antibody production by symptomatology in SARS-CoV-2 convalescent individuals
por: Saraf, Sharada, et al.
Publicado: (2022)

Differential antibody production by symptomatology in SARS-CoV-2 convalescent individuals
por: Saraf, Sharada, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_065u3sik30h94mmncleugh9q0n